Receptor tyrosine kinase inhibitors: Are they real tumor killers?
Research output: Contribution to journal › Review article › Contributed › peer-review
Contributors
Abstract
Inhibiting tumor growth by targeting the tumor vasculature was first proposed by Judah Folkman almost 40 years ago. Since then, different approaches and numerous drugs and agents have been developed to achieve this goal, either with the aim of inhibiting tumor neoangiogenesis or normalizing the tumor vasculature. Among the most promising therapeutic targets are receptor tyrosine kinases (RTKs), some of which are predominantly expressed on tumor endothelial cells, although they are sometimes also present on tumor cells. The majority of RTK inhibitors investigated over the past two decades competes with ATP at the active site of the kinase and therefore block the phosphorylation of intracellular targets. Some of these drugs have been approved for therapy, whereas others are still in clinical trials. Here, we discuss the scientific basis, current status, problems and future prospects of RTK inhibition in anti-tumor therapy.
Details
Original language | English |
---|---|
Pages (from-to) | 540-554 |
Number of pages | 15 |
Journal | International journal of cancer |
Volume | 138 |
Issue number | 3 |
Publication status | Published - 1 Feb 2016 |
Peer-reviewed | Yes |
External IDs
PubMed | 25716346 |
---|---|
ORCID | /0000-0002-9467-780X/work/162845989 |
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- receptor tyrosine kinase, small molecule inhibitor, tumor angiogenesis, VEGF receptor